Staidson (Beijing) Biopharmaceuticals Co., Ltd. (300204.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 19.65

From 52W high−48.21%

Volume13.48M

Market capCNY 11.37B

P/E (TTM)−146.2x

P/S (TTM)52.7x

Div yield—

Key dataSep 18, 2026

Open

CNY 19.65

From 52W high

−48.21%

Volume

13.48M

Market cap

CNY 11.37B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−169.4x

P/E (TTM)

−146.2x

RSI (14)

38.2

MomentumView details →

1D Return

−5.32%

YTD Return

−27.34%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−146.2x

EV/EBITDA

−169.4x

EV/Sales

52.6x

P/S (TTM)

52.7x

P/B (TTM)

5.6x

ProfitabilityView details →

Gross Margin

77.17%

Net Margin

−41.12%

EBITDA Margin

−31.05%

ROE (TTM)

−10.36%

ROA (TTM)

−6.55%

Asset Turnover

0.16x

GrowthView details →

Revenue YoY

−30.42%

EPS YoY

+41.45%

FCF YoY

—

Revenue CAGR 3Y

−26.25%

EPS CAGR 3Y

+46.67%

EBITDA YoY

—

MomentumView details →

1D Return

−5.32%

YTD Return

−27.34%

1Y Return

−44.08%

RSI (14)

38.2

vs 50D SMA

−12.10%

vs 200D SMA

−22.50%

Capital & dividendView details →

Debt/Equity

0.15x

Current Ratio

2.00x

Quick Ratio

1.85x

Div Yield

—

Div Rate

—

Div Growth 1Y

+167.23%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

203.92M

Net Income (TTM)

−83.86M

Op. CF (TTM)

−130.31M

Latest newsMore news →

China's National Medical Products Administration accepted the clinical trial application (CXSL2601019) for a new indication of Bojianing (pomitease alfa for injection) by Jiangsu Beijiatai Biotechnology, a subsidiary of Staidson, for the treatment of major surgical bleeding.3d ago

Similar companies

利尔化学002258.SZ 宝武镁业002182.SZ 平潭发展000592.SZ 石药景峰000908.SZ 奥飞娱乐002292.SZ 四川九洲000801.SZ Find similar companies →

Latest newsMore news →

China's National Medical Products Administration accepted the clinical trial application (CXSL2601019) for a new indication of Bojianing (pomitease alfa for injection) by Jiangsu Beijiatai Biotechnology, a subsidiary of Staidson, for the treatment of major surgical bleeding.3d ago